Immune dysfunction and epidermal barrier dysfunction are two key factors in the atopic dermatitis (AD) pathogenesis. “In my belief, the most promising approach is not improving the barrier function, but primarily using anti-inflammatory agents,” said Prof. Eric Simpson (Oregon Health & Science University, USA) . At present, there are two important therapeutic gaps: “We need a more efficacious topical therapy than non-steroidals without significant burning or safety concern, and we would love to have pills in moderate-to-severe disease,” said Prof. Simpson. JAK inhibitors have the potential to fill these gaps. At present, there are two phase 2 trials with JAK inhibitors in AD.
A Japanese phase 2 study was performed with the topical JAK inhibitor delgocitinib in adult patients with moderate-to-severe AD . In this trial, the JAK inhibitor ointment, applied twice daily, led to a significant dose dependent change in the EASI (each dose P<0.01 compa...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Psoriasis and Biologics: The Beat Goes On Next Article
Hair Loss: No Reason for Therapeutic Nihilism »
Table of Contents: AAD 2019
Atopic Dermatitis: Many New Therapies in the Pipeline
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
What's New and Hot in Acne
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.